{
  "approved_at_utc": null,
  "subreddit": "stocks",
  "selftext": "Pfizer PFE, +1.34% was upgraded to buy from neutral at UBS, which also lifted its price target to $60 from $52. UBS said the oral antiviral paxlovid will generate at least $14 billion in sales next year, which it said was 40% above consensus expectations. Combined with the Comirnaty vaccine, there's potentially $50 billion of sales potential from its COVID franchise next year, UBS said. Pfizer closed Friday at $52.78 and has gained 43% this year.\n\n[https://www.marketwatch.com/story/pfizer-lifted-to-buy-at-ubs-which-says-covid-franchise-sales-could-hit-50-billion-next-year-2021-12-13?mod=mw\\_latestnews](https://www.marketwatch.com/story/pfizer-lifted-to-buy-at-ubs-which-says-covid-franchise-sales-could-hit-50-billion-next-year-2021-12-13?mod=mw_latestnews)",
  "author_fullname": "t2_ans93q0w",
  "saved": false,
  "mod_reason_title": null,
  "gilded": 0,
  "clicked": false,
  "title": "Pfizer lifted to buy at UBS, which says COVID franchise sales could hit $50 billion next year",
  "link_flair_richtext": [],
  "subreddit_name_prefixed": "r/stocks",
  "hidden": false,
  "pwls": 6,
  "link_flair_css_class": "",
  "downs": 0,
  "top_awarded_type": null,
  "hide_score": false,
  "name": "t3_rfd29o",
  "quarantine": false,
  "link_flair_text_color": "dark",
  "upvote_ratio": 0.84,
  "author_flair_background_color": null,
  "subreddit_type": "public",
  "ups": 274,
  "total_awards_received": 0,
  "media_embed": {},
  "author_flair_template_id": null,
  "is_original_content": false,
  "user_reports": [],
  "secure_media": null,
  "is_reddit_media_domain": false,
  "is_meta": false,
  "category": null,
  "secure_media_embed": {},
  "link_flair_text": "Company Analysis",
  "can_mod_post": false,
  "score": 274,
  "approved_by": null,
  "is_created_from_ads_ui": false,
  "author_premium": false,
  "thumbnail": "",
  "edited": false,
  "author_flair_css_class": null,
  "author_flair_richtext": [],
  "gildings": {},
  "content_categories": null,
  "is_self": true,
  "mod_note": null,
  "created": 1639392543,
  "link_flair_type": "text",
  "wls": 6,
  "removed_by_category": null,
  "banned_by": null,
  "author_flair_type": "text",
  "domain": "self.stocks",
  "allow_live_comments": true,
  "selftext_html": "&lt;!-- SC_OFF --&gt;&lt;div class=\"md\"&gt;&lt;p&gt;Pfizer PFE, +1.34% was upgraded to buy from neutral at UBS, which also lifted its price target to $60 from $52. UBS said the oral antiviral paxlovid will generate at least $14 billion in sales next year, which it said was 40% above consensus expectations. Combined with the Comirnaty vaccine, there&amp;#39;s potentially $50 billion of sales potential from its COVID franchise next year, UBS said. Pfizer closed Friday at $52.78 and has gained 43% this year.&lt;/p&gt;\n\n&lt;p&gt;&lt;a href=\"https://www.marketwatch.com/story/pfizer-lifted-to-buy-at-ubs-which-says-covid-franchise-sales-could-hit-50-billion-next-year-2021-12-13?mod=mw_latestnews\"&gt;https://www.marketwatch.com/story/pfizer-lifted-to-buy-at-ubs-which-says-covid-franchise-sales-could-hit-50-billion-next-year-2021-12-13?mod=mw_latestnews&lt;/a&gt;&lt;/p&gt;\n&lt;/div&gt;&lt;!-- SC_ON --&gt;",
  "likes": null,
  "suggested_sort": null,
  "banned_at_utc": null,
  "view_count": null,
  "archived": false,
  "no_follow": false,
  "is_crosspostable": false,
  "pinned": false,
  "over_18": false,
  "awarders": [],
  "media_only": false,
  "link_flair_template_id": "1235582c-6848-11eb-96e8-0e132357f477",
  "can_gild": false,
  "spoiler": false,
  "locked": false,
  "author_flair_text": null,
  "treatment_tags": [],
  "visited": false,
  "removed_by": null,
  "num_reports": null,
  "distinguished": null,
  "subreddit_id": "t5_2qjfk",
  "author_is_blocked": false,
  "mod_reason_by": null,
  "removal_reason": null,
  "link_flair_background_color": "#d6890a",
  "id": "rfd29o",
  "is_robot_indexable": true,
  "report_reasons": null,
  "author": "rugerapatt",
  "discussion_type": null,
  "num_comments": 18,
  "send_replies": true,
  "whitelist_status": "all_ads",
  "contest_mode": false,
  "mod_reports": [],
  "author_patreon_flair": false,
  "author_flair_text_color": null,
  "permalink": "/r/stocks/comments/rfd29o/pfizer_lifted_to_buy_at_ubs_which_says_covid/",
  "parent_whitelist_status": "all_ads",
  "stickied": false,
  "url": "https://www.reddit.com/r/stocks/comments/rfd29o/pfizer_lifted_to_buy_at_ubs_which_says_covid/",
  "subreddit_subscribers": 3376657,
  "created_utc": 1639410440,
  "num_crossposts": 0,
  "media": null,
  "is_video": false,
  "original_created_utc": 1639392543,
  "the_new_excerpt": "Pfizer PFE, +1.34% was upgraded to buy from neutral at UBS, which also lifted\nits price target to $60 from $52. UBS said the oral antiviral paxlovid will\ngenerate at least $14 billion in sales next year, which it said was 40% above\nconsensus expectations. Combined with the Comirnaty vaccine,…",
  "localize": [
    {
      "locale": "ja",
      "the_new_excerpt": "ファイザーPFE, +1.34%は、UBSで中立から買いに格上げされ、また、UBSも上方修正した。\nUBSは、経口抗ウイルス剤パクスロビドについて、目標株価が52ドルから60ドルになると述べた。\n来年の売上は少なくとも140億ドルで、これは40％上回るという。\nコンセンサス予想 コミルナティワクチンと組み合わせることで、...",
      "title": "COVIDフランチャイズの売上が来年500億ドルに達するとするUBSでファイザーが買いに持ち上げられる"
    },
    {
      "locale": "zh",
      "the_new_excerpt": "瑞银将辉瑞公司PFE, +1.34%的评级从中性上调至买入。\n瑞银称，口服抗病毒药物paxlovid将在明年产生至少140亿美元的销售额，其目标价从52美元升至60美元。\n明年将产生至少140亿美元的销售额，它说这比一致预期高40%。\n协商一致的预期。与Comirnaty疫苗结合起来，...",
      "title": "辉瑞公司在瑞银集团被提升为买入，瑞银集团称明年COVID专营权销售额可能达到500亿美元"
    },
    {
      "locale": "zh-Hant",
      "the_new_excerpt": "瑞銀將輝瑞公司PFE, +1.34%的評級從中性上調至買入。\n瑞銀稱，口服抗病毒藥物paxlovid將在明年產生至少140億美元的銷售額，其目標價從52美元升至60美元。\n明年將產生至少140億美元的銷售額，它說這比一致預期高40%。\n協商一致的預期。與Comirnaty疫苗結合起來，...",
      "title": "輝瑞公司在瑞銀集團被提升爲買入，瑞銀集團稱明年COVID專營權銷售額可能達到500億美元"
    }
  ],
  "source_updated_at": 1639734119985
}